VenHub Global and Follett Higher Education have formed a strategic partnership to deploy VenHub's autonomous Smart Stores across Follett-served college and university campuses in the US. This collaboration aims to create a scalable, 24/7 retail channel offering convenience products, campus merchandise, and essentials beyond traditional store hours. The stores will be customized to each campus's branding and placed in high-traffic locations like residence halls and student centers. This initiative expands Follett's retail reach and provides students and visitors with flexible, round-the-clock access to campus goods.
VenHub and Follett Higher Education's new partnership is the subject, with Pluang's Consumer Cyclical sector data providing market context. As of Oct 26, 2026 18:31 WIB, out of 134 priced US Consumer Cyclical stocks tradable on Pluang, 75 rose and 33 fell. Notable movers include NEGG at USD 9.55 with a -1.55% change, AZO at USD 3,153.00 down by -1.49%, and RACE at USD 398.55 up by +1.34%.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
